SkyKnight Apex Infusion investment to back California infusion provider

SkyKnight Capital has agreed to make an investment in Apex Infusion, a Signal Hill, California-based provider of infusion services with approximately 40 ambulatory infusion suite locations. The SkyKnight Apex Infusion investment adds a new backer to a healthcare services company founded in 2006, although financial terms were not disclosed.

FFL Partners will continue as a minority investor in Apex, according to PE Hub. The announcement did not disclose SkyKnight’s ownership stake, valuation, financing structure or expected closing timetable.

Apex is led by Moussie Haile, its chief executive and co-founder. Don Wu, managing director at SkyKnight Capital, said the firm plans to work with Apex’s leadership and FFL as the company continues to build its role in alternate-site infusion care for patients, providers and payors.

What is Apex Infusion?

Apex Infusion is an infusion services provider based in Signal Hill, California. The company operates about 40 ambulatory infusion suite locations, according to PE Hub, and has been in operation since 2006.

Ambulatory infusion suites are care settings outside the traditional inpatient hospital environment where patients can receive infusion therapy. In the context of the deal announcement, Apex is positioned as an alternate-site infusion provider serving patients, healthcare providers and payors.

Who advised SkyKnight and Apex?

SkyKnight was advised by Guggenheim Securities, Holland & Knight, Bass Berry & Sims and Morrison Foerster. Apex was advised by Raymond James, Willkie Farr & Gallagher and Polsinelli, according to PE Hub.

The presence of multiple legal and financial advisers reflects the transaction’s corporate and healthcare dimensions, although the companies did not release additional information on regulatory approvals, debt financing or any planned operational changes.

What does FFL’s minority role mean?

FFL Partners remaining a minority investor means it will retain an ownership position that is not described as controlling in the announcement. The size of FFL’s retained stake and any governance rights attached to it were not disclosed.

For Apex, the disclosed facts point to continuity in management, with Haile remaining identified as chief executive and co-founder, and continuity among investors through FFL’s ongoing minority position. SkyKnight’s investment adds capital and sponsorship for the company’s next phase, according to comments attributed to Wu.

The transaction sits within a broader healthcare services market in which investors have shown interest in care delivery models outside hospitals. PE Hub reported no financial metrics for Apex, including revenue, earnings, patient volume or geographic distribution beyond its Signal Hill base and its approximately 40 suite locations.

This story draws on original reporting from PE Hub.